Verona Pharma PLC (LSE:VRP) - Share price - Overview

Stock Report

Verona Pharma PLC VRP

Last Price
GBX133.00

Day Change
-0.50|-0.37%

As of 28/04/2017
16:36:06 BST | GBX
Minimum 15 Minutes Delay.

Last Close133.50p
Day Range131.00 - 135.00
Mkt Cap68.31Mil
52-Wk Range120.77 - 210.00
Yield %0.00
ISINGB00BYW2KH80
Volume20,157
P/E-8.87
P/SInfinity
P/CF-8.10

Share Price

Total Returns 28/04/2017

 Chg (%)  
More ...
Verona Pharma PLC-7.32 
FTSE 100 TR GBP-1.33
 
Financials
201420152016
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-3.79-8.98-7.02
Net Profit-2.76-7.49-5.02
Reported EPS-16.00-37.00-15.00
Balance Sheet
Current Assets11.265.5743.81
Non Current Assets1.872.272.33
Total Assets13.137.8446.14
Current Liabilities0.531.8110.87
Total Liabilities0.532.4111.67
Total Equity12.615.4334.47
Cash Flow
Operating Cash Flow-3.83-7.06-7.12
Net Change in Cash9.37-6.4535.57
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-14.05-27.06--4.92---
201855.2677.10-1.73---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
27/04/2017PurchaseVikas Sinha131.37177,776233,541.00
26/04/2017PurchaseDr. David Ebsworth132.0013,37317,652.00
01/03/2017PurchaseDr. Jan-Anders Karlsson149.007,75011,548.00
28/02/2017PurchaseDr. Jan-Anders Karlsson149.0012,00017,880.00

Company Profile

Verona Pharma PLC is a clinical-stage biopharmaceutical company engaged in the development of novel drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease, cystic fibrosis and asthma.

Sector

Biotechnology

Market Position

1020 of 1849 Companies

Index

FTSE AIM All Share

Outlook

(27/02/2017) no outlook statement

Next Event 13/09/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)21.0213.9116.17
Div Yld (E)0.003.874.14
PEG (E)0.000.271.07
ROCE-18.57180.2518.61
Op Mrgn0.00-5.76-0.67
EPS Grwth0.0067.5732.65
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. David Ebsworth
Chief Executive OfficerDr. Jan-Anders Karlsson
Chief Financial OfficerPiers Morgan
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.